Health Technology Nichi-Iko Pharmaceutical Co., Ltd. Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
Mar 2021
JPY USD Revenue 188,218M 1,774.68M Gross Profit 21,245M 200.31M Operating income -9,867M -93.03M Income before tax 636M 5.99M Net income -4,180M -39.41M EBITDA 3,350M 31.58M Diluted EPS -65.27 -0.61 Dividends Per Share 25 0.23 Total Assets 363,572M 3,290.24M Total liabilities 251,134M 2,272.70M Total equity 111,167M 1,006.03M Operating cash flow 5,006M 47.20M Currency in JPY Currency in USD
Historical Data Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
149,263M
164,717M
166,592M
190,076M
188,218M
Gross Profit
37,611M
40,803M
33,158M
37,320M
21,245M
Operating income
10,026M
13,200M
7,221M
7,572M
-9,867M
Income before tax
5,963M
9,067M
8,903M
7,396M
636M
Net income
4,796M
8,069M
6,864M
5,133M
-4,180M
EBITDA
17,091M
22,179M
16,987M
19,443M
3,350M
Diluted EPS
84.08
142.92
114.03
80.12
-65.27
Dividends Per Share
30
30
30
30
25
Total Assets
268,900M
278,364M
306,838M
336,819M
363,572M
Total liabilities
185,725M
190,819M
190,511M
219,644M
251,134M
Total equity
83,171M
87,542M
116,323M
115,827M
111,167M
Operating cash flow
-4,076M
18,925M
23,811M
18,450M
5,006M
Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Revenue
1,378.39M
1,486.18M
1,502.25M
1,748.21M
1,774.68M
Gross Profit
347.32M
368.15M
299.00M
343.24M
200.31M
Operating income
92.58M
119.09M
65.11M
69.64M
-93.03M
Income before tax
55.06M
81.80M
80.28M
68.02M
5.99M
Net income
44.28M
72.80M
61.89M
47.21M
-39.41M
EBITDA
157.82M
200.11M
153.18M
178.82M
31.58M
Diluted EPS
0.77
1.28
1.02
0.73
-0.61
Dividends Per Share
0.27
0.27
0.27
0.27
0.23
Total Assets
2,413.17M
2,617.43M
2,772.17M
3,119.99M
3,290.24M
Total liabilities
1,666.74M
1,794.25M
1,721.19M
2,034.58M
2,272.70M
Total equity
746.39M
823.14M
1,050.93M
1,072.91M
1,006.03M
Operating cash flow
-37.64M
170.75M
214.71M
169.69M
47.20M
Valuation Measures
Mar 2021
PER -- ROA -1.19% ROE -3.68% Operating margin -5.24% Profit margin -2.22%
Key executives
President & Representative Director:
Yuichi Tamura
Finance Manager:
Naoyuki Okada
Head-Compliance Management & Guidance:
Yasutomo Sai
Director, VP, Head-CSR, ESG & Business Creation:
Kenji Akane
Executive Officer & Personnel Manager:
Keiichi Arakawa Shareholders
TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (11.8%)
Medipal Holdings Corp. (9.7%)
Hokuhoku Financial Group, Inc. (3.9%)
Nomura Asset Management Co., Ltd. (2.4%)
The Vanguard Group, Inc. (1.8%)
Dimensional Fund Advisors LP (1.8%)
Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
Nichi-Iko Pharmaceutical Co., Ltd. (1.3%)
Nikko Asset Management Co., Ltd. (1.1%)
Daiwa Asset Management Co. Ltd. (1.1%)
Related Companies
Nichi Iko Pharmaceutical Co. /Toyama Daini Kojo/
Nichi-Iko Gifu Plant Co., Ltd.
Nichi-Iko Pharma Tech Co., Ltd.
Elmed Co., Ltd.
Nichi Iko Pharmaceutical Trust
SterRx LLC
Nichi-Iko Pharmaceutical Employee Incentive Plan
Nichiiko Pharma KK
Nichiiko Osaka KK
Yakuhan Pharmaceutical Co., Ltd.
Sagent Pharmaceuticals, Inc.
Kobayashi Pharmaceutical Industries Co. Ltd.
Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
Oriental Pharmaceutical Co., Ltd.
Teikoku Medix Co., Ltd.
Japan Galen, Inc.
Maruko Pharmaceutical Co. Ltd.
Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
Dr. Reddy's Laboratories Ltd.
Cumberland Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 22 Oct, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
